Search

Your search keyword '"Essler, M."' showing total 404 results
Start Over Author "Essler, M."
404 results on '"Essler, M."'

7. Lutetium-177-PSMA-Radioligandentherapie: Konsensus im Rahmen der GKV-finanzierten Versorgung zwischen den Hochschulkliniken in Aachen, Bonn, Düsseldorf, Essen und Köln und dem MDK Nordrhein

Author

Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Böhme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Höhling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Müller, H-W., Müller, S. C., Ost, E., Rahbar, K., Reifenhäuser, W., Schäfers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B., and Essler, M.

Published
2018
Full Text
View/download PDF

9. Theranostics in nuclear medicine practice

Author

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, and Essler M

Subjects
theranostics, nuclear medicine, personalized medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Anna Yordanova,1 Elisabeth Eppard,2 Stefan Kürpig,2 Ralph A Bundschuh,3 Stefan Schönberger,4 Maria Gonzalez-Carmona,5 Georg Feldmann,6 Hojjat Ahmadzadehfar,1 Markus Essler1 1Department of Nuclear Medicine (Clinical Nuclear Medicine), 2Department of Nuclear Medicine (Radiochemistry), 3Department of Nuclear Medicine (Medical Physics and PET), 4Department of Paediatric Haematology and Oncology, 5Department of Medicine 1, 6Department of Medicine 3, University Hospital Bonn, Bonn, Germany Abstract: The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets can help predict if a patient will benefit from a particular treatment. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents has been continually increasing. In this article, important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with a well-known radioiodine therapy in patients with thyroid cancer and then progresses through various approaches for the treatment of advanced cancer with targeted therapies. The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices. Keywords: theranostics, nuclear medicine, personalized medicine, PET/CT, therapy, diagnostics

Published
2017

10. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience

Author

Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, and Schild HH

Subjects
Radioembolization, hepatocellular carcinoma, HCC, locoregional therapy, liver, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Carsten Meyer,1,* Claus Christian Pieper,1,* Hojjat Ahmadzadehfar,2 Nina Alexandra Lampe,1 Eva Maria E Matuschek,1 Thomas Adrian Maschke,1 Simon Jonas Enkirch,1 Markus Essler,2 Ulrich Spengler,3 Hans Heinz Schild1 1Department of Radiology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany, 2Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany, 3Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany *These authors contributed equally to this work Purpose: To determine the value of radioembolization (RE) for treatment of unresectable hepatocellular carcinoma (HCC). Patients and methods: Records of patients undergoing RE for unresectable HCC were retrospectively reviewed. Biochemical and clinical toxicities, imaging response (according to modified Response Evaluation Criteria In Solid Tumors), time-to-progression (TTP) and overall survival (OS) were analyzed. Data were stratified according to clinical and procedural parameters. Univariate and multivariate analyses were performed. Results: One hundred and fifteen patients (89 male, mean age 69.3 years) underwent 158 REs (119 resin-, 39 glass-based) (Barcelona Clinic Liver Cancer [BCLC]-A: 6.1%, B: 33.9%, C: 60.0%). Median clinical follow-up was 5.9 (0.9–83.5) months. No grade 4 or 5 clinical toxicities were noted. Objective response rate was 35.6%; disease control rate was 76.7%. Median TTP of the treated part of the liver was 4 (0.9–45.4) months. 108/115 patients died during follow-up (median OS 8.4 [0.3–82.8] months after first RE [BCLC-A: 52.8 months, BCLC-B: 12.4 months, BCLC-C: 6.1 months]). On multivariate analysis, baseline Eastern Co-operative Oncology Group status

Published
2017

11. Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes

Author

Rahbar, K., additional, Essler, M., additional, Eiber, M., additional, La Fougere, C., additional, Prasad, V., additional, Fendler, W. P., additional, Rassek, P., additional, Hasa, E., additional, Dittmann, H., additional, Papst, K. M., additional, Kurtinecz, M., additional, Schmall, A., additional, Verholen, F., additional, and Sartor, O. A., additional

Published
2023
Full Text
View/download PDF

15. Brain Tumors

Author

Garibotto, V., Baskin, A., Essler, M., Foerster, S., Drzezga, A., Haller, S., Merlini, L., Pyka, T., Vargas, M.-I., Weber, D., Ratib, Osman, editor, Schwaiger, Markus, editor, and Beyer, Thomas, editor

Published
2013
Full Text
View/download PDF

17. Lymphoma, Lung and other Tumors

Author

Eiber, M., Baskin, A., Essler, M., Holzapfel, K., Ratib, O., Scheidbauer, K., Willi, J.-P., Ratib, Osman, editor, Schwaiger, Markus, editor, and Beyer, Thomas, editor

Published
2013
Full Text
View/download PDF

18. 1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study

Author

O'Sullivan, J., primary, Heinrich, D., additional, Castro Marcos, E., additional, George, S., additional, Song, D.Y., additional, Dizdarevic, S., additional, Baldari, S., additional, Essler, M., additional, de Jong, I.J., additional, Lastoria, S., additional, Hammerer, P.G., additional, Tombal, B., additional, James, N.D., additional, Verholen, F., additional, Meltzer, J., additional, Sandström, P., additional, and Sartor, O., additional

Published
2022
Full Text
View/download PDF

19. 1392P Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes

Author

Rahbar, K., primary, Essler, M., additional, Eiber, M., additional, la Fougère, C., additional, Prasad, V., additional, Fendler, W.P., additional, Rassek, P., additional, Hasa, E., additional, Dittmann, H., additional, Bundschuh, R.A., additional, Pabst, K.M., additional, Kurtinecz, M., additional, Schmall, A., additional, Verholen, F., additional, and Sartor, O., additional

Published
2022
Full Text
View/download PDF

22. DEPROMP-Studie: Prospektive Evaluation der Detektionsrate klinisch signifikanter Prostatakarzinome in der Primärdiagnostik durch Kombination von PSMA-PET/CT- und multiparametrischer MRT-Fusionsstanzbiopsie

Author

Krausewitz, P, Gärtner, F, Bundschuh, R, Essler, M, Attenberger, U, Luetkens, J, Muders, M, Kristiansen, G, Hauser, S, Ellinger, J, Ritter, M, Krausewitz, P, Gärtner, F, Bundschuh, R, Essler, M, Attenberger, U, Luetkens, J, Muders, M, Kristiansen, G, Hauser, S, Ellinger, J, and Ritter, M

Published
2022

24. Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

Author

Essler, M., additional, Santhanam Sundar, S.S., additional, Sabina Dizdarevic, S.D., additional, Song, D.S.DanielY., additional, Neeraj Agarwal, N.A., additional, Saby George, S.G., additional, Shore, N.S.NealD., additional, Milena Kurtinecz, M.K., additional, Frank Verholen, F.V., additional, Per Sandström, P.S., additional, Oliver Sartor, O.S., additional, and George, D.G.DanielJ., additional

Published
2022
Full Text
View/download PDF

26. 593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

Author

Higano, C.S., primary, Dizdarevic, S., additional, Sundar, S., additional, Agarwal, N., additional, Essler, M., additional, Song, D., additional, George, S., additional, Shore, N.D., additional, Kurtinecz, M., additional, Verholen, F., additional, Sandström, P., additional, Sartor, O., additional, and George, D.J., additional

Published
2021
Full Text
View/download PDF

32. Safety And Clinical Outcomes Of Radium-223 With Concomitant Radiotherapy Or Subsequent Treatment With The Investigational Agent 177Lu-PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: An Interim Analysis Of The REASSURE Study

Author

Song, D., primary, Zimberg, S.H., additional, Conti, P., additional, la Fougère, C., additional, Essler, M., additional, Kramer, G., additional, Ellinger, J., additional, Sylvester, J.E., additional, Paganelli, G., additional, Peer, A., additional, Bögemann, M., additional, George, S., additional, Tomaszewski, J., additional, Meltzer, J., additional, Sandström, P., additional, Babajanyan, S., additional, Nordquist, L., additional, and Sartor, O., additional

Published
2020
Full Text
View/download PDF

35. Amyloid-related changes of basal forebrain volume and precuneus functional connectivity in Subjective Cognitive Decline patients

Author

Daamen, M, additional, Li, S, additional, Scheef, L, additional, Gärtner, F, additional, Amthauer, H, additional, Buchert, R, additional, Bürger, K, additional, Drzezga, A, additional, Ertl-Wagner, B, additional, Essler, M, additional, Haynes, JD, additional, Krause, BJ, additional, Laske, C, additional, Priller, J, additional, Ramirez, A, additional, Reimold, M, additional, Rominger, A, additional, Scheffler, K, additional, Schmitt, A, additional, Schneider, A, additional, Spottke, A, additional, Teipel, SJ, additional, Wagner, M, additional, Düzel, E, additional, Jessen, F, additional, Peters, O, additional, and Boecker, H, additional

Published
2020
Full Text
View/download PDF

40. Vaskuläre Expression vom prostataspezifischen Membranantigen in Nierentumoren: Implikationen für bildgebende Studien und prognostische Rolle

Author

Tolkach, Y, Spatz, S, Bundschuh, R, Jung, K, Stephan, C, Busch, J, Ralla, B, Rabien, A, Feldmann, G, Brossart, P, Ahmadzadehfar, H, Essler, M, Toma, M, Müller, S, Ellinger, J, Hauser, S, and Kristiansen, G

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Prostataspezifisches Membranantigen (PSMA) wird von Endothelien der tumorassoziierten Gefäßen in vielen Tumoren exprimiert. Das Ziel dieser Studie war eine umfassende Evaluation des PSMA in Nierenzellkarzinom (RCC), insbesondere mit Bezug zur potenziellen Anwendung als Target[zum vollständigen Text gelangen Sie über die oben angegebene URL], 63. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2018
Full Text
View/download PDF

48. Lutetium-177-PSMA radioligand therapy. Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Dusseldorf, Essen, and Cologne and the MDK Nordrhein

Author

Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Boehme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Hoehling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Mueller, H-W., Mueller, S. C., Ost, E., Rahbar, K., Reifenhaeuser, W., Schaefers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B., Essler, M., Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Boehme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Hoehling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Mueller, H-W., Mueller, S. C., Ost, E., Rahbar, K., Reifenhaeuser, W., Schaefers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B., and Essler, M.

Abstract

In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer. This therapy combines the radionuclide Lutetium-177, which has been therapeutically used in nuclear medicine for many years, with a molecular target of the transmembrane prostate-specific membrane antigen expressed by prostate cancer cells. Since there are no prospective randomized studies on Lu-177-PSMA-RLT and the question of reimbursement has repeatedly been the subject of review by the MDK Nordrhein (Medischenische Dienst der Krankenversicherung), there was a desire because of the increasing number of patients being treated to clarify under which circumstances Lu-177-PSMA-RLT can be reimbursed by German statutory health insurance. The goals of this article are to help treating physicians understand how this new therapy option works, to integrate it in the overall therapy concept for castration-resistant metastatic prostate cancer, and, above all, to use Lu-177-PSMA-RLT-based on the current data-at the right place in the therapy sequence of castration-resistant metastatic prostate cancer.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results